Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

× No keyword cloud information.

5 in total

1. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.

Authors: E Schmidt; S Reimer; N Kruse; E B Bröcker; D Zillikens
Journal: Clin Exp Immunol Date: 2001-04 Impact factor: 4.330

Review 2. Harnessing the anti-inflammatory effects of topical dapsone for management of acne.

Authors: Leon H Kircik
Journal: J Drugs Dermatol Date: 2010-06 Impact factor: 2.114

Review 3. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.

Authors: Mariarosaria Boccellino; Lucio Quagliuolo; Concetta Alaia; Anna Grimaldi; Raffaele Addeo; Giovanni Francesco Nicoletti; Richard Eric Kast; Michele Caraglia
Journal: Curr Med Res Opin Date: 2016-08-11 Impact factor: 2.580

4. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

Authors: Smita S Joshi; Sara Ortiz; Joslyn N Witherspoon; Alfred Rademaker; Dennis P West; Roger Anderson; Sara E Rosenbaum; Mario E Lacouture
Journal: Cancer Date: 2010-08-15 Impact factor: 6.860

Review 5. Dapsone and sulfones in dermatology: overview and update.

Authors: Y I Zhu; M J Stiller
Journal: J Am Acad Dermatol Date: 2001-09 Impact factor: 11.527

5 in total

7 in total

Review 1. Emerging Technologies to Target Drug Delivery to the Skin - the Role of Crystals and Carrier-Based Systems in the Case Study of Dapsone.

Authors: Gabriela Schneider-Rauber; Debora Fretes Argenta; Thiago Caon
Journal: Pharm Res Date: 2020-11-09 Impact factor: 4.200

2. Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Authors: M E Lacouture
Journal: Ann Oncol Date: 2018-04-01 Impact factor: 32.976

Review 3. Pruritus Associated with Targeted Anticancer Therapies and Their Management.

Authors: Jennifer Wu; Mario E Lacouture
Journal: Dermatol Clin Date: 2018-07 Impact factor: 3.478

4. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

Authors: J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover
Journal: Invest New Drugs Date: 2021-01-03 Impact factor: 3.651

Review 5. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.

Authors: Mario Lacouture; Vincent Sibaud
Journal: Am J Clin Dermatol Date: 2018-11 Impact factor: 7.403

6. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.

Authors: Young Saing Kim; Jun Ho Ji; Sung Yong Oh; Suee Lee; Seok Jae Huh; Ji Hyun Lee; Ki-Hoon Song; Choon Hee Son; Mee Sook Roh; Gyeong Won Lee; Jeeyun Lee; Seung Tae Kim; Chan Kyu Kim; Joung Soon Jang; In Gyu Hwang; Hee Kyung Ahn; Lee Chun Park; So Yeon Oh; Seong-Geun Kim; Sang-Cheol Lee; Do-Hyoung Lim; Soon Il Lee; Jung Hun Kang
Journal: Oncologist Date: 2019-09-06

Review 7. Dermatologic conditions in women receiving systemic cancer therapy.

Authors: Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal: Int J Womens Dermatol Date: 2019-11-07

7 in total